Eplerenone to Prevent Myocardial Fibrosis in Congenital Heart Disease

Trial Profile

Eplerenone to Prevent Myocardial Fibrosis in Congenital Heart Disease

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Eplerenone (Primary)
  • Indications Heart disorders
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Feb 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Dec 2014 Planned End Date changed from 1 Jan 2016 to 1 Jul 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top